Could PCSO-524® be a potential adjuvant treatment to sleep therapy in the management of depression?

• Published in: Psychiatry research 2021-01, Vol.295, p.113590-113590, Article 113590
• Main Authors: Arakaki, Felipe H., Xerfan, Ellen M.S., Galduróz, José Carlos F., Tufik, Sergio, Andersen, Monica L.
• Format: Article
• Language: English
• Subjects: Depression; Neuroinflammation; PCSO-524; Sleep
• ISSN: 0165-1781; 1872-7123
• DOI: 10.1016/j.psychres.2020.113590

•Depressive disorders can be accompanied by poor sleep quality, and both may aggravate neuroinflammation.•High levels of inflammatory cytokines are associated with psychiatric disorders, including depression.•PCSO-524® (Lyprinol®/Omega XL®) has an anti-inflammatory effect that could play a role in neuroinflammation.•Pro-inflammatory and depressogenic cytokines, such as IL-6 and TNF-α, could increase due to impaired sleep.•Sleep therapy combined with PCSO-524® could be an adjuvant treatment for depression. Sleep is essential in neural system homeostasis due to its regulation of the immunological system and inflammatory cytokines. Poor sleep quality can induce a pro-inflammatory state and aggravate depressive symptoms. Depression has been linked with high levels of peripheral and central pro-inflammatory markers. In this context, we highlight a possible role for PCSO-524®, a nutritional supplement extracted from the New Zealand green lipped mussel that has already been shown to have anti-inflammatory effects, as an adjuvant treatment for depression alongside sleep therapy. Although there are not as yet any studies on its use in treating depression, it has been demonstrated to be a promising treatment in another condition that has been linked with inflammation, attention deficit/hyperactivity disorder, and in some other neurodegenerative disorders. Therefore, PCSO-524®, associated with good sleep quality, could be an option to reinforce depression management.